Oppenheimer Cites “Abundance of Support” for Capricor’s Deramiocel Ahead of November FDA Decision

Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.